Dermatofibroma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (21 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Dermatofibroma}} | {{Dermatofibroma}} | ||
{{CMG}} | {{CMG}}, {{AE}}{{Homa}} | ||
==Overview== | ==Overview== | ||
==Epidemiology and Demographics== | Dermatofibroma is a common [[benign]] [[skin lesion]] that is seen in almost 3000 dermatophatology [[laboratory]] specimens per 100,000 ones. As most of [[patients]] with dermatofibroma are [[asymptomatic]], the worldwide [[incidence]] of dermatofibroma is unknown. [[Patients]] of all age groups may develop dermatofibroma. Although, it is more occurred in 20s to 40s ages. There is no [[racial]] predilection to dermatofibroma. [[Female]] are more commonly affected by dermatofibroma than [[male]]. The [[female]] to [[male]] [[ratio]] is approximately 2 to 1. | ||
==Epidemiology == | |||
===Prevalence=== | |||
*Dermatofibroma is a common [[benign]] [[skin lesion]] that is seen in almost 3000 dermatophatology [[laboratory]] specimens per 100,000 ones. <ref name="AgarwalGopinath2017">{{cite journal|last1=Agarwal|first1=Atin|last2=Gopinath|first2=Arun|last3=Tetzlaff|first3=Michael T.|last4=Prieto|first4=Victor G.|title=Phosphohistone-H3 and Ki67|journal=The American Journal of Dermatopathology|volume=39|issue=7|year=2017|pages=504–507|issn=0193-1091|doi=10.1097/DAD.0000000000000690}}</ref><ref name="BuehlerWeisman2017">{{cite journal|last1=Buehler|first1=Darya|last2=Weisman|first2=Paul|title=Soft Tissue Tumors of Uncertain Histogenesis|journal=Clinics in Laboratory Medicine|volume=37|issue=3|year=2017|pages=647–671|issn=02722712|doi=10.1016/j.cll.2017.06.005}}</ref> | |||
===Incidence=== | |||
*As most of [[patients]] with dermatofibroma are [[asymptomatic]], the worldwide [[incidence]] of dermatofibroma is unknown.<ref name="BuehlerWeisman2017">{{cite journal|last1=Buehler|first1=Darya|last2=Weisman|first2=Paul|title=Soft Tissue Tumors of Uncertain Histogenesis|journal=Clinics in Laboratory Medicine|volume=37|issue=3|year=2017|pages=647–671|issn=02722712|doi=10.1016/j.cll.2017.06.005}}</ref><ref name="BandyopadhyayBesra2016">{{cite journal|last1=Bandyopadhyay|first1=MousumiRoy|last2=Besra|first2=Mrinal|last3=Dutta|first3=Somasree|last4=Sarkar|first4=Somnath|title=Dermatofibroma: Atypical presentations|journal=Indian Journal of Dermatology|volume=61|issue=1|year=2016|pages=121|issn=0019-5154|doi=10.4103/0019-5154.174131}}</ref> | |||
== Demographics == | |||
===Age=== | |||
*[[Patients]] of all age groups may develop dermatofibroma. Although, it is more common in the 20s to 40s ages. <ref name="AgarwalGopinath2017">{{cite journal|last1=Agarwal|first1=Atin|last2=Gopinath|first2=Arun|last3=Tetzlaff|first3=Michael T.|last4=Prieto|first4=Victor G.|title=Phosphohistone-H3 and Ki67|journal=The American Journal of Dermatopathology|volume=39|issue=7|year=2017|pages=504–507|issn=0193-1091|doi=10.1097/DAD.0000000000000690}}</ref><ref name="BuehlerWeisman2017">{{cite journal|last1=Buehler|first1=Darya|last2=Weisman|first2=Paul|title=Soft Tissue Tumors of Uncertain Histogenesis|journal=Clinics in Laboratory Medicine|volume=37|issue=3|year=2017|pages=647–671|issn=02722712|doi=10.1016/j.cll.2017.06.005}}</ref><ref name="HanChang2011">{{cite journal|last1=Han|first1=Tae Young|last2=Chang|first2=Hee Sun|last3=Lee|first3=June Hyun Kyung|last4=Lee|first4=Won-Mi|last5=Son|first5=Sook-Ja|title=A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma)|journal=Annals of Dermatology|volume=23|issue=2|year=2011|pages=185|issn=1013-9087|doi=10.5021/ad.2011.23.2.185}}</ref> | |||
===Race=== | |||
*There is no [[racial]] predilection to dermatofibroma.<ref name="AgarwalGopinath2017">{{cite journal|last1=Agarwal|first1=Atin|last2=Gopinath|first2=Arun|last3=Tetzlaff|first3=Michael T.|last4=Prieto|first4=Victor G.|title=Phosphohistone-H3 and Ki67|journal=The American Journal of Dermatopathology|volume=39|issue=7|year=2017|pages=504–507|issn=0193-1091|doi=10.1097/DAD.0000000000000690}}</ref><ref name="BandyopadhyayBesra2016">{{cite journal|last1=Bandyopadhyay|first1=MousumiRoy|last2=Besra|first2=Mrinal|last3=Dutta|first3=Somasree|last4=Sarkar|first4=Somnath|title=Dermatofibroma: Atypical presentations|journal=Indian Journal of Dermatology|volume=61|issue=1|year=2016|pages=121|issn=0019-5154|doi=10.4103/0019-5154.174131}}</ref> | |||
===Gender=== | ===Gender=== | ||
[[Category: | *[[Female]] are more commonly affected by dermatofibroma than [[male]]. The [[female]] to [[male]] [[ratio]] is approximately 2 to 1.<ref name="AgarwalGopinath2017">{{cite journal|last1=Agarwal|first1=Atin|last2=Gopinath|first2=Arun|last3=Tetzlaff|first3=Michael T.|last4=Prieto|first4=Victor G.|title=Phosphohistone-H3 and Ki67|journal=The American Journal of Dermatopathology|volume=39|issue=7|year=2017|pages=504–507|issn=0193-1091|doi=10.1097/DAD.0000000000000690}}</ref><ref name="BandyopadhyayBesra2016">{{cite journal|last1=Bandyopadhyay|first1=MousumiRoy|last2=Besra|first2=Mrinal|last3=Dutta|first3=Somasree|last4=Sarkar|first4=Somnath|title=Dermatofibroma: Atypical presentations|journal=Indian Journal of Dermatology|volume=61|issue=1|year=2016|pages=121|issn=0019-5154|doi=10.4103/0019-5154.174131}}</ref><ref name="ŞenelYuyucu Karabulut2015">{{cite journal|last1=Şenel|first1=E.|last2=Yuyucu Karabulut|first2=Y.|last3=Doğruer Şenel|first3=S.|title=Clinical, histopathological, dermatoscopic and digital microscopic features of dermatofibroma: a retrospective analysis of 200 lesions|journal=Journal of the European Academy of Dermatology and Venereology|volume=29|issue=10|year=2015|pages=1958–1966|issn=09269959|doi=10.1111/jdv.13092}}</ref><ref name="HanChang2011">{{cite journal|last1=Han|first1=Tae Young|last2=Chang|first2=Hee Sun|last3=Lee|first3=June Hyun Kyung|last4=Lee|first4=Won-Mi|last5=Son|first5=Sook-Ja|title=A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma)|journal=Annals of Dermatology|volume=23|issue=2|year=2011|pages=185|issn=1013-9087|doi=10.5021/ad.2011.23.2.185}}</ref> | ||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Latest revision as of 21:17, 29 July 2020
|
Dermatofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dermatofibroma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Dermatofibroma epidemiology and demographics |
|
Risk calculators and risk factors for Dermatofibroma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
Dermatofibroma is a common benign skin lesion that is seen in almost 3000 dermatophatology laboratory specimens per 100,000 ones. As most of patients with dermatofibroma are asymptomatic, the worldwide incidence of dermatofibroma is unknown. Patients of all age groups may develop dermatofibroma. Although, it is more occurred in 20s to 40s ages. There is no racial predilection to dermatofibroma. Female are more commonly affected by dermatofibroma than male. The female to male ratio is approximately 2 to 1.
Epidemiology
Prevalence
- Dermatofibroma is a common benign skin lesion that is seen in almost 3000 dermatophatology laboratory specimens per 100,000 ones. [1][2]
Incidence
- As most of patients with dermatofibroma are asymptomatic, the worldwide incidence of dermatofibroma is unknown.[2][3]
Demographics
Age
- Patients of all age groups may develop dermatofibroma. Although, it is more common in the 20s to 40s ages. [1][2][4]
Race
Gender
- Female are more commonly affected by dermatofibroma than male. The female to male ratio is approximately 2 to 1.[1][3][5][4]
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
References
- ↑ 1.0 1.1 1.2 1.3 Agarwal, Atin; Gopinath, Arun; Tetzlaff, Michael T.; Prieto, Victor G. (2017). "Phosphohistone-H3 and Ki67". The American Journal of Dermatopathology. 39 (7): 504–507. doi:10.1097/DAD.0000000000000690. ISSN 0193-1091.
- ↑ 2.0 2.1 2.2 Buehler, Darya; Weisman, Paul (2017). "Soft Tissue Tumors of Uncertain Histogenesis". Clinics in Laboratory Medicine. 37 (3): 647–671. doi:10.1016/j.cll.2017.06.005. ISSN 0272-2712.
- ↑ 3.0 3.1 3.2 Bandyopadhyay, MousumiRoy; Besra, Mrinal; Dutta, Somasree; Sarkar, Somnath (2016). "Dermatofibroma: Atypical presentations". Indian Journal of Dermatology. 61 (1): 121. doi:10.4103/0019-5154.174131. ISSN 0019-5154.
- ↑ 4.0 4.1 Han, Tae Young; Chang, Hee Sun; Lee, June Hyun Kyung; Lee, Won-Mi; Son, Sook-Ja (2011). "A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma)". Annals of Dermatology. 23 (2): 185. doi:10.5021/ad.2011.23.2.185. ISSN 1013-9087.
- ↑ Şenel, E.; Yuyucu Karabulut, Y.; Doğruer Şenel, S. (2015). "Clinical, histopathological, dermatoscopic and digital microscopic features of dermatofibroma: a retrospective analysis of 200 lesions". Journal of the European Academy of Dermatology and Venereology. 29 (10): 1958–1966. doi:10.1111/jdv.13092. ISSN 0926-9959.